Welcome to the GARDASIL Access Program

The GARDASIL Access Program is currently undergoing a strategic evaluation that may result in changes to application requirements. Therefore, the Program is not accepting new applications at the present time. Please visit the site again in April 2012 for a Program update. Thank you in advance for your cooperation.

Through the GARDASIL Access Program, Merck & Co., Inc. (Whitehouse Station, NJ, USA) has pledged to donate at least 3 million doses of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] for use in approved projects in eligible lowest income countries throughout the world.

The GARDASIL Access Program enables organizations and institutions in eligible lowest income countries to gain operational experience designing and implementing smaller scale human papillomavirus (HPV) vaccination projects, with the goal of supporting the development of successful child and adolescent immunization models. Click here for more information on the GARDASIL Access Program.

To date, 920,000 doses of GARDASIL have shipped to 20 participants in 18 countries, enough to vaccinate more than 306,600 eligible girls. Click here to learn more about the participating organizations and institutions that have completed or are currently implementing HPV vaccination projects supported by the GARDASIL Access Program.

Eligibility Criteria
Find out if your organization or institution is eligible to apply for the program

Newsletter, December 2010
The third GARDASIL® Access Program Newsletter is now available